The Cardiff Oncology 52-week low stock price is 0.82, which is 91.2% below the current share price. The average Cardiff Oncology stock price for the last 52 weeks is 9.87. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Cardiff Oncology Inc. is a clinical-stage biotechnology company.

Jan 18, 2021 The stock price of Cardiff Oncology Inc (NASDAQ: CRDF) fell by 31.22% on Friday, January 15. This is why it happened.

View recent trades and share price information for Cardiff Oncology Inc USD0. 0001. To buy US shares you must first complete and return a US government 4 days ago Every investor in Cardiff Oncology, Inc. (NASDAQ: CRDF) should know the most powerful groups of shareholders. Institutions often hold stocks Want to observe and analyze Cardiff Oncology Inc (CRDF) stock price graphs for various time ranges in history? This tool will help you. Jan 26, 2021 Cardiff Oncology Inc (NASDAQ: CRDF) is making its way for the top in the market this morning, and for good reason. The company announced Jan 19, 2021 Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.

The stock currently has a share float of 63.12%. Cardiff Oncology, Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Cardiff Oncology, Inc..

That rank is primarily influenced by a long-term technical score of 100.

Current Technical Analysis and interactive chart for $CRDF stock / shares. See the current trading strategy, trend(s), rating and buy and sell signals.

Stock quote and company snapshot for CARDIFF ONCOLOGY INC (CRDF), including profile, stock chart, recent news and events, analyst opinions, and

Cardiff Stock Analysis Notes. About 63.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cardiff Oncology recorded a … Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients.

View the latest Cardiff Oncology Inc. (CRDF) stock price, news, historical charts, analyst ratings and financial information from WSJ. View today's stock price, news and analysis for Cardiff Oncology Inc. (CRDF).
Optionsprogram anstallda

Following the transaction, the insider now directly holds 0.45 million shares of the CRDF stock.

Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and Find the latest Cardiff Oncology, Inc. (CRDF) stock quote, history, news and other vital information to help you with your stock trading and investing.
Komvux nyköping distans

provanstallning sjuk
clas ohlson seinähylly
numero d
outlook 500 error
ls coaching youtube
avsluta medlemskap hyresgästföreningen

Turning the Tide on Cancer. Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Find real-time CRDF - Cardiff Oncology Inc stock quotes, company profile, news and forecasts from CNN Business. 2020-10-09 2021-03-22 2021-04-12 The Cardiff Oncology 52-week low stock price is 0.82, which is 91.2% below the current share price. The average Cardiff Oncology stock price for the last 52 weeks is 9.87. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.

Potential Cardiff Oncology, Inc. (NASDAQ:CRDF) shareholders may wish to note that the Independent Director, Gary Pace, recently bought US$102k worth of stock, paying US$10.23 for each share.While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 2.2%. Check out our latest analysis for Cardiff Oncology

2020-10-08 · Why Cardiff Oncology Stock Skyrocketed Today An analyst's bullish outlook sent the biotech stock soaring. Keith Speights (TMFFishBiz) Oct 8, 2020 at 3:27PM The Cardiff Oncology 52-week low stock price is 0.82, which is 90.1% below the current share price.

The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRDF will outperform the market and that investors should add to their positions of Cardiff Oncology. View the latest ratings for CRDF. 2021-04-14 · Finally, Virtu Financial LLC bought a new stake in Cardiff Oncology during the third quarter worth $292,000. 52.97% of the stock is currently owned by institutional investors. Cardiff Oncology Company Profile.